20
Participants
Start Date
September 15, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
PITAC
Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor effect, respectively. Based on the available data and experience from 11 PITAC procedures at OPC, PITAC with cisplatin, oxaliplatin and doxorubicin for intrapleural administration is expected to be well tolerated with a minimal of nausea, subcutaneous emphysema and transient chest pains.
RECRUITING
Odense PIPAC Center, Department of Surgery, Odense University Hospital, Odense
Odense University Hospital
OTHER